Capricor Therapeutics Reports First Quarter 2023 Financial Results ...
10-K Filing - Capricor Therapeutics
The aggregate market value of the registrant's common stock held by non-affiliates of the registrant as of June 30, 2023 was approximately $ 119,715,277 , based ...
10-K Filing - Capricor Therapeutics
As of March 16, 2023, there were 25,255,154 shares of the registrant's common stock, par value $0.001 per share, issued and outstanding. . DOCUMENTS ...
Published Password Lists: 1 - Ineapple
... first expert erica eatshit dreaming dollars doghouse dog disturbed dianne ... quarter quaker punk portia popo poiuy pioneers phantasy peaches1 p@ssw0rd ...
Press Releases :: Capricor Therapeutics, Inc. (CAPR)
Capricor Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update. May 13, 2020 4:30 pm EDT. Capricor Therapeutics to Present ...
Capricor Therapeutics Reports Fourth Quarter and Full Year 2022 ...
“In 2022, we continued to advance our clinical development program for CAP-1002 in patients with Duchenne Muscular Dystrophy (DMD), highlighted ...
10-K Filing - Capricor Therapeutics
x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2020.
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate. Update. -Enrollment Complete in ...
Press Releases :: Capricor Therapeutics, Inc. (CAPR)
Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update. May 09, 2024 9:15 am EDT. Capricor Therapeutics to Present ...
Press Releases :: Capricor Therapeutics, Inc. (CAPR)
2023, 2022, 2021, 2020, 2019, 2018, 2017, 2016, 2015, 2014, 2013 ... Capricor Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate ...
Press Release, titled “Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update”, dated. August 7, 2023 ...
10-Q Filing - Capricor Therapeutics
Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. . for the quarterly period ended March 31, 2024.
10-K Filing - Capricor Therapeutics
This Annual Report on Form 10-K contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, or the Securities Act, ...
Press Releases :: Capricor Therapeutics, Inc. (CAPR)
Capricor Therapeutics Provides Corporate Update and Reports First Quarter 2016 Financial Results. May 05, 2016 4:05 pm EDT. Capricor Therapeutics to Hold ...
Additionally, as a result of the merger between Nile and Capricor and in accordance with the terms of the merger agreement, each outstanding share of Capricor ...
Press Releases :: Capricor Therapeutics, Inc. (CAPR)
Capricor Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update. May 12, 2017 6:30 am EDT. Capricor Therapeutics Provides ...
tm2426251-2_424b5 - none - 6.6719021s - Capricor Therapeutics
We file annual, quarterly and current reports, proxy statements ... These forward-looking statements relate to future events or to our future financial ...
Our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, as filed with the SEC on March 16, 2017, accompanies this proxy statement. This ...
Capricor Therapeutics Announces Intent to File Biologics License ...
More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the ...
Press Releases :: Capricor Therapeutics, Inc. (CAPR)
Mar 08, 2023 9:00 am EST. Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15. Mar 02 ...
Press Releases :: Capricor Therapeutics, Inc. (CAPR)
... Annual Meeting. May 13, 2021 4:05 pm EDT. Capricor Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update. May 12, 2021 9:00 ...